GON Stock Overview
A late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Geron Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.80 |
| 52 Week High | US$5.20 |
| 52 Week Low | US$1.58 |
| Beta | 0.51 |
| 11 Month Change | 4.48% |
| 3 Month Change | -5.42% |
| 1 Year Change | 114.55% |
| 33 Year Change | 188.84% |
| 5 Year Change | 198.59% |
| Change since IPO | -57.03% |
Recent News & Updates
Recent updates
Shareholder Returns
| GON | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 10.2% | -0.7% | 0.2% |
| 1Y | 114.6% | -17.2% | 8.5% |
Return vs Industry: GON exceeded the German Biotechs industry which returned -17.2% over the past year.
Return vs Market: GON exceeded the German Market which returned 8.5% over the past year.
Price Volatility
| GON volatility | |
|---|---|
| GON Average Weekly Movement | 6.4% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: GON has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: GON's weekly volatility has decreased from 15% to 6% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 141 | Chip Scarlett | www.geron.com |
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
Geron Corporation Fundamentals Summary
| GON fundamental statistics | |
|---|---|
| Market cap | €2.36b |
| Earnings (TTM) | -€193.21m |
| Revenue (TTM) | €28.31m |
83.5x
P/S Ratio-12.2x
P/E RatioIs GON overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GON income statement (TTM) | |
|---|---|
| Revenue | US$29.48m |
| Cost of Revenue | US$112.38m |
| Gross Profit | -US$82.90m |
| Other Expenses | US$118.29m |
| Earnings | -US$201.19m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.33 |
| Gross Margin | -281.22% |
| Net Profit Margin | -682.47% |
| Debt/Equity Ratio | 28.7% |
How did GON perform over the long term?
See historical performance and comparison